Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). The aim of the project is to develop an innovative, effective and safe candidate for medicine used in the treatment of selected solid cancers. According to WHO data, cancers form the largest group of civilisation diseases (World Cancer Report, 2014). Recent reports point to the important role of ubiquitin-proteasom (UPS) pathway, in particular the ubiquitine activating enzyme (UAE), in regulating protein production and thus in the survival of cancer cells. Inhibition of the key protein ubiquitylation enzyme may be an effective alternative to solid tumour therapies. The first UPS inhibitor to inhibit proteases is bortezomib, registered in haematological therapies. However, its side effects, intravenous route of administration and lack of efficiency in the treatment of solid tumours, force the search for alternative drugs. The project will be conducted in 10 stages, which will last a total of 45 months. The first 9 stages will include industrial research. The synthesis of the leading UAE inhibitor will be developed to the GMP scale. Analytical methods and final formulation will be developed. Also, analyses will be conducted to intensify research on the mechanism of action and looking for biomarkers to respond to therapy. In addition, ADMET, in vivo and toxicological studies were planned to confirm the efficacy and safety of the compound. In parallel, the lead relationship will be optimised in case data disqualifying him as a drug candidate. The identified biomarkers will be verified in vivo and retrospectively using tumours from patients. A test will be developed and validated to select patients for clinical trials. The final stage of the project,